Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

癌症研究 泛素连接酶 PD-L1 细胞周期蛋白依赖激酶6 免疫检查点 杜瓦卢马布 蛋白质降解 卡林 细胞生物学 免疫系统 免疫疗法 彭布罗利珠单抗 激酶 生物 泛素 化学 细胞周期蛋白依赖激酶2 蛋白激酶A 免疫学 生物化学 基因
作者
Jinfang Zhang,Xia Bu,Haizhen Wang,Yasheng Zhu,Yan Geng,Naoe Taira Nihira,Yuyong Tan,Yanpeng Ci,Fei Wu,Xiangpeng Dai,Jianping Guo,Yuhan Huang,Caoqi Fan,Shancheng Ren,Yinghao Sun,Gordon James Freeman,Piotr Siciński,Wenyi Wei
出处
期刊:Nature [Nature Portfolio]
卷期号:553 (7686): 91-95 被引量:1064
标识
DOI:10.1038/nature25015
摘要

Abundance of PD-L1, the ligand of the anti-cancer immunotherapy target PD-1, is negatively regulated by poly-ubiquitination via the cyclin D–CDK4/cullin 3–SPOP axis and PD-1 blockade treatment in mice improved survival when combined with CDK4/6 inhibitors. Immune checkpoint blockade therapy with PD-1 or PD-L1 inhibitors has been approved for the treatment of several types of cancer, but only a small percentage of patients respond to this from of treatment. Wenyi Wei and colleagues report that the abundance of the PD-L1 protein is negatively regulated during cell cycle progression, in part through the activity of the upstream cyclin D–CDK4–SPOP–FZR1 signalling pathway. CDK4/6 inhibitor treatment increases PD-L1 levels and promotes immune evasion in vitro and in vivo. On the other hand, combined treatment with a CDK4/6 inhibitor and a PD-1 blocker has greater anti-tumour efficacy than treatment with each drug alone in mouse models. This combined approach has the potential to improve the treatment of patients with cancer. Treatments that target immune checkpoints, such as the one mediated by programmed cell death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinical benefit1,2. However, many patients with cancer fail to respond to compounds that target the PD-1 and PD-L1 interaction, and the underlying mechanism(s) is not well understood3,4,5. Recent studies revealed that response to PD-1–PD-L1 blockade might correlate with PD-L1 expression levels in tumour cells6,7. Hence, it is important to understand the mechanistic pathways that control PD-L1 protein expression and stability, which can offer a molecular basis to improve the clinical response rate and efficacy of PD-1–PD-L1 blockade in patients with cancer. Here we show that PD-L1 protein abundance is regulated by cyclin D–CDK4 and the cullin 3–SPOP E3 ligase via proteasome-mediated degradation. Inhibition of CDK4 and CDK6 (hereafter CDK4/6) in vivo increases PD-L1 protein levels by impeding cyclin D–CDK4-mediated phosphorylation of speckle-type POZ protein (SPOP) and thereby promoting SPOP degradation by the anaphase-promoting complex activator FZR1. Loss-of-function mutations in SPOP compromise ubiquitination-mediated PD-L1 degradation, leading to increased PD-L1 levels and reduced numbers of tumour-infiltrating lymphocytes in mouse tumours and in primary human prostate cancer specimens. Notably, combining CDK4/6 inhibitor treatment with anti-PD-1 immunotherapy enhances tumour regression and markedly improves overall survival rates in mouse tumour models. Our study uncovers a novel molecular mechanism for regulating PD-L1 protein stability by a cell cycle kinase and reveals the potential for using combination treatment with CDK4/6 inhibitors and PD-1–PD-L1 immune checkpoint blockade to enhance therapeutic efficacy for human cancers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被dan1029采纳,获得10
刚刚
风吹麦浪的应助被dan1029采纳,获得10
刚刚
大模型的应助被dan1029采纳,获得10
刚刚
领导范儿的应助被dan1029采纳,获得10
刚刚
风吹麦浪的应助被dan1029采纳,获得10
刚刚
风吹麦浪的应助被dan1029采纳,获得10
刚刚
风吹麦浪的应助被dan1029采纳,获得10
刚刚
wings完成签到,获得积分10
2秒前
俏皮的孤丹完成签到 ,获得积分10
2秒前
2秒前
不爱喝酒的应助被有人喜欢蓝采纳,获得50
3秒前
情怀的应助被无辜的擎汉采纳,获得10
3秒前
路哈哈完成签到,获得积分10
3秒前
上官若男的应助被小龙采纳,获得10
3秒前
llllll完成签到,获得积分10
4秒前
JXY189发布了新的文献求助10
4秒前
4秒前
5秒前
feike完成签到,获得积分10
5秒前
星空_完成签到 ,获得积分10
5秒前
林撞树完成签到,获得积分10
6秒前
柒年完成签到,获得积分10
6秒前
噗噗完成签到,获得积分10
6秒前
给咖啡加点糖完成签到 ,获得积分10
7秒前
zyy发布了新的文献求助10
7秒前
时衍发布了新的文献求助10
7秒前
emm发布了新的文献求助10
7秒前
7秒前
8秒前
叉叉发布了新的文献求助10
8秒前
Megan发布了新的文献求助10
8秒前
ljh完成签到,获得积分10
8秒前
苦行僧完成签到,获得积分10
9秒前
CAOHOU的应助被如懿采纳,获得10
9秒前
9秒前
9秒前
proudzhu完成签到,获得积分10
10秒前
Tycoon完成签到,获得积分10
10秒前
10秒前
木子完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181949
求助须知:如何正确求助?哪些是违规求助? 9571702
关于积分的说明 21819272
捐赠科研通 7778399
什么是DOI,文献DOI怎么找? 3433572
关于科研通互助平台的介绍 2557769
邀请新用户注册赠送积分活动 2479630